Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data
Open Access
- 1 September 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 30 (3) , 801-807
- https://doi.org/10.1002/hep.510300329
Abstract
Relapse after interferon (IFN) therapy for chronic hepatitis C virus (HCV) infection occurs in 50% of patients after the initial response. The benefit of retreatment with IFN alone has not been assessed in large controlled studies. To assess the effectiveness and the tolerability of IFN retreatment and to identify the optimal second course regimen, we performed a meta-analysis of individual patient's data on a set of 549 patients (mean age 43.8 years; 12.2 SD, men: 65%) who had an end-of-treatment biochemical response to a first IFN course and then relapsed. Retreatment was started within 24 months after the end of the first course. Biochemical end-of-treatment responses (ETR) and sustained responses (SR) were observed in 405 of 549 (73.8%; 95% confidence interval [CI] 70.1-77.5) and in 124 of 549 (22.6%; CI 19.1-26.1) patients, respectively. One hundred seventy-five of 404 patients (43.3%; CI 38.6-48.2) developed an end-of-treatment, biochemical, and virological response when retreated. A biochemical and virological SR to retreatment occurred in 73 of 494 (14.8%; CI 11.7-18) patients. Thirty-two patients (5.8%; CI 3.5-7.8) stopped retreatment for adverse effects. Biochemical and virological SR was predicted independently by logistic regression analysis using a negative HCV RNA at the end of the first cycle of IFN (P= .01) and by retreatment with a high IFN dose (P= .03). Age, cirrhosis, genotype, and γ-glutamyl transferase levels before retreatment were not significant by multivariate analysis. The excellent tolerability of IFN monotherapy retreatment makes it an option for patients who transiently cleared HCV-RNA during their first IFN course. Patients should be retreated with a high IFN dose regardless of the strength of the dose received during the previous course of treatment.Keywords
Funding Information
- Hoffman La-Roche, Basel to EUROHEP for data collection and statistical analysis
This publication has 24 references indexed in Scilit:
- Severe anemia following combined α-interferon/ribavirin therapy of chronic hepatitis CJournal of Hepatology, 1998
- Re-treatment of chronic hepatitis C with consensus interferonHepatology, 1998
- Therapy of hepatitis C: Re-treatment with alpha interferonHepatology, 1997
- Retreatment with 24-week course of interferon-α for patients with chronic hepatitis CInternational Hepatology Communications, 1996
- Re‐treatment of interferon‐resistant patients with chronic hepatitis C with interferon‐αJournal of Viral Hepatitis, 1995
- Retreatment of chronic hepatitis C virus infectionPublished by Elsevier ,1994
- Retreatment with interferon in chronic hepatitis CJournal of Hepatology, 1994
- Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assayJournal of General Virology, 1993
- Serum HCV RNA Levels in Patients with Chronic Hepatitis C Given a Second Course of Interferon alpha-2b Treatment after Relapse following Initial TreatmentScandinavian Journal of Infectious Diseases, 1993
- Retreatment of Chronic Hepatitis C with Interferon-The Journal of Infectious Diseases, 1992